HK Stock Market Move | EVEREST MED-B(01952) rose by over 3% in early trading. The first AI-driven self-developed mRNA tumor therapeutic vaccine has completed the first patient administration.

EVEREST MED-B (01952) rose more than 3% in the morning session, closing at a 1.29% increase at HK$51.11, with a turnover of HK$42.81 million. On the news front, on March 6th, Revotek New Shine announced that its independently developed mRNA personalized tumor therapeutic vaccine EVM16 has successfully completed the first patient dosing at Peking University Cancer Hospital, indicating that Revotek New Shine's independently owned tumor new antigen artificial intelligence (AI) algorithm system and clinically validated mRNA technology platform have successfully entered the human trial stage. It is reported that EVM16 is a new mRNA personalized tumor therapeutic vaccine developed by Revotek New Shine, driven by an AI algorithm to identify tumor new antigens. Based on the unique tumor cell mutations of each patient, using the independently developed and self-iterative EVER-NEO-1 "Mystical" tumor new antigen artificial intelligence AI algorithm system, it identifies tumor new antigens with high immunogenicity and designs mRNA therapeutic vaccines encoding dozens of tumor new antigens.